UndisclosedDivestiture / carve-outHealthcare & Life Sciences
PharmaLogic to buy Lantheus' radiopharma CDMO business
PharmaLogic, an independent radiopharmaceutical CDMO, is buying Lantheus' (NASDAQ: LNTH) CDMO business and its Springfield, New Jersey theranostic manufacturing site, which will join its Agilera franchise. The deal includes a long-term agreement for Agilera to manufacture lutetium Lu 177 dotatate for Lantheus. Financial terms were not disclosed.
Why it matters: PharmaLogic says the deal creates the first transatlantic therapeutic CDMO platform for radioligand therapies.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →